Attorneys Danielle Gold and Brendan McDonough, from our Drug and Medical Device Litigation unit, are presenting at the New Jersey Association for Justice (NJAJ) upcoming seminar.
Meadowlands Seminar 2020, A Digital Experience: Education, Networking & Exhibits is a 3-day event on Monday through Wednesday, December 7-9. Both Gold and McDonough are scheduled to share their knowledge on December 9.
The Meadowlands Seminar is being conducted on the same platform that was used for the Boardwalk Seminar 2020 held during the summer. This digital format makes it possible for participants to choose individual webinars based on their specific needs and interests. This NJAJ event offers 24 programs taught in a total of 65 separate webinars by esteemed legal professionals.
Gold Discusses Eye Damage from Elmiron
Gold speaks during the first seminar session on Wednesday, beginning at 9:00 a.m. and concluding at 10:15 a.m. This session focuses on Mass Tort Litigation Updates. Gold addresses side effects of the drug Elmiron.
“I’m excited to have the opportunity to share recent developments in this litigation with my colleagues at NJAJ,” says Gold. “NJAJ has kept me informed on a number of issues that have helped me further my career, and I’m happy to add my own small part to that body of knowledge.”
Elmiron, pentosan polysulfate sodium, is an FDA-approved drug intended to help relieve bladder pain in patients diagnosed with interstitial cystitis. Concerns have arisen that pentosan polysulfate sodium is linked to pigmentary maculopathy. As a result, on June, 16, 2020, the package insert was changed to warn of the risks. Chronic exposure to Elmiron may damage a person’s retina and lead to irreversible vision loss.
McDonough Shares SNAP Removal Outlook
Also on Wednesday, McDonough presents during the second seminar session of the day, beginning at 11:00 a.m. and concluding at 12:15 p.m. This seminar session addresses Mass Tort Avoiding Landmines: Before and After the Case. McDonough discusses the growing use of the snap removal procedural tool.
“Being selected to share what I know at this NJAJ seminar is an honor. I’m excited to impart litigation experience regarding snap removals with my colleagues,” explains McDonough. “It’s especially important that attorneys be made aware of procedures that may affect our cases.”
Snap removal involves attorneys for corporate defendants exploiting a loophole in federal law. They move suits filed against them very quickly from state to federal court before the defendant has even been served. Typically, these lawsuits involve product liability and mass tort actions brought against large pharmaceutical companies.
Ellen Relkin, Chair of our Drug and Medical Device Litigation practice group has testified before Congress, urging legislators to pass legislation to close the snap removal loophole.
The New Jersey Association for Justice is the statewide association dedicated to trial attorneys. It has more than 2,700 members. NJAJ helps member stay current on trial bar critical issues, share member experience, earn CLE credits, and have a voice in the State House and courthouse.